On November 3, 2025, Sarepta Therapeutics reported that its Phase 3 ESSENCE trial for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 did not meet the primary endpoint, though ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback